CSL Limited (CSLLY) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with CSLLY. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

CSL reports in US dollars, which makes its earnings directly comparable to the CSLLY price once the four-ADRs-per-share ratio is applied: one ASX share at about A$185 is roughly US$129, or about US$32 per ADR. At around 20 times underlying earnings, CSL trades well below the 30 to 40 times multiple it commanded for most of the last decade, which reflects both slower expected growth and lower confidence after the guidance cuts. FY26 dividends totalled roughly US$2.92 per share (an interim of about US$1.30 and a final of US$1.62), and the company is continuing an on-market buyback of about US$1.1 billion in FY27. The statutory loss is driven by non-cash impairments and restructuring charges, while operating cash flow held near US$3.5 billion.

For the fiscal year ending Jun 2027, the 17 analysts publishing estimates on CSLLY expect earnings of $1.54 per share (-76% on the year before) and revenue of $15.8 billion (-0.3%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. CSL Limited next reports on August 17, 2026, which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering CSLLY do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Jun 2028: analysts expect earnings of $1.68 per share, +9.5% on the fiscal year ending Jun 2027 estimate of $1.54. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether CSL Limited can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Immunoglobulin recovery at CSL Behring, Plasma cost and margin rebuild, Specialty products and the pipeline. The risk cited most often against it is the most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CSLLY is it a buy page. This page deliberately stops at the numbers.